144 related articles for article (PubMed ID: 17114663)
1. Plasma osteopontin is an independent prognostic marker for head and neck cancers.
Petrik D; Lavori PW; Cao H; Zhu Y; Wong P; Christofferson E; Kaplan MJ; Pinto HA; Sutphin P; Koong AC; Giaccia AJ; Le QT
J Clin Oncol; 2006 Nov; 24(33):5291-7. PubMed ID: 17114663
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma.
Xie H; Song J; Du R; Liu K; Wang J; Tang H; Bai F; Liang J; Lin T; Liu J; Fan D
Dig Liver Dis; 2007 Feb; 39(2):167-72. PubMed ID: 17161983
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers.
Shimada Y; Watanabe G; Kawamura J; Soma T; Okabe M; Ito T; Inoue H; Kondo M; Mori Y; Tanaka E; Imamura M
Oncology; 2005; 68(2-3):285-92. PubMed ID: 16015046
[TBL] [Abstract][Full Text] [Related]
4. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas.
Le QT; Sutphin PD; Raychaudhuri S; Yu SC; Terris DJ; Lin HS; Lum B; Pinto HA; Koong AC; Giaccia AJ
Clin Cancer Res; 2003 Jan; 9(1):59-67. PubMed ID: 12538452
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of elevated osteopontin levels in head and neck cancer patients.
Eto M; Kodama S; Nomi N; Uemura N; Suzuki M
Auris Nasus Larynx; 2007 Sep; 34(3):343-6. PubMed ID: 17254728
[TBL] [Abstract][Full Text] [Related]
6. Soluble Tie-2 receptor levels independently predict locoregional recurrence in head and neck squamous cell carcinoma.
Homer JJ; Greenman J; Drevs J; Marme D; Stafford ND
Head Neck; 2002 Aug; 24(8):773-8. PubMed ID: 12203803
[TBL] [Abstract][Full Text] [Related]
7. [Osteopontin as a potential biomarker of metastasis and recurrence for hepatocellular carcinoma].
Cui BK; Zhang CQ; Zhang Y; Yuan YF; Zhang YQ; Shi M; Chen MS; Li SP; Li JQ
Ai Zheng; 2006 Jul; 25(7):876-9. PubMed ID: 16831281
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of osteopontin expression in T1 and T2 tongue cancers.
Chien CY; Su CY; Chuang HC; Fang FM; Huang HY; Chen CM; Chen CH; Huang CC
Head Neck; 2008 Jun; 30(6):776-81. PubMed ID: 18228527
[TBL] [Abstract][Full Text] [Related]
9. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma.
Kim J; Ki SS; Lee SD; Han CJ; Kim YC; Park SH; Cho SY; Hong YJ; Park HY; Lee M; Jung HH; Lee KH; Jeong SH
Am J Gastroenterol; 2006 Sep; 101(9):2051-9. PubMed ID: 16848813
[TBL] [Abstract][Full Text] [Related]
10. [The prognostic significance of preoperative plasma level of osteopontin in combination with intercellular adhesion molecule-1 for patients with hepatocellular carcinoma].
Zhang H; Ren N; Ye QH; Sun HC; Wang L; Liu YK; Tang ZY; Qin LX
Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):985-8. PubMed ID: 16194354
[TBL] [Abstract][Full Text] [Related]
11. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival.
Singhal H; Bautista DS; Tonkin KS; O'Malley FP; Tuck AB; Chambers AF; Harris JF
Clin Cancer Res; 1997 Apr; 3(4):605-11. PubMed ID: 9815727
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study.
Reiniger IW; Wolf A; Welge-Lüssen U; Mueller AJ; Kampik A; Schaller UC
Am J Ophthalmol; 2007 Apr; 143(4):705-7. PubMed ID: 17386288
[TBL] [Abstract][Full Text] [Related]
13. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer.
Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3337-43. PubMed ID: 16740755
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of primary tumor volume after concurrent chemoradiation with daily low-dose cisplatin for advanced-stage head and neck carcinoma.
Hoebers FJ; Pameijer FA; de Bois J; Heemsbergen W; Balm AJ; Schornagel JH; Rasch CR
Head Neck; 2008 Sep; 30(9):1216-23. PubMed ID: 18642295
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma.
Van Hal NL; Van Dongen GA; Ten Brink CB; Heider KH; Rech-Weichselbraun I; Snow GB; Brakenhoff RH
Clin Cancer Res; 1999 Nov; 5(11):3534-41. PubMed ID: 10589769
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of mitotic and apoptotic index and the DNA cytometry in head and neck cancer.
Smilek P; Dusek L; Veselý K; Rottenberg J; Kostrica R
Neoplasma; 2005; 52(3):199-207. PubMed ID: 15875080
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of the combined modality therapy for advanced cervical metastatic head and neck squamous cell carcinoma.
Preuss SF; Klussmann JP; Wittekindt C; Damm M; Semrau R; Drebber U; Guntinas-Lichius O
Eur J Surg Oncol; 2007 Apr; 33(3):358-63. PubMed ID: 17157472
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
Riedel F; Zaiss I; Herzog D; Götte K; Naim R; Hörmann K
Anticancer Res; 2005; 25(4):2761-5. PubMed ID: 16080523
[TBL] [Abstract][Full Text] [Related]
20. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma.
Zhong LP; Zhu HG; Zhang CP; Chen WT; Zhang ZY
Int J Oral Maxillofac Surg; 2007 Mar; 36(3):230-4. PubMed ID: 16965897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
